A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.


BACKGROUND Vaccines against pandemic A/H1N1 influenza are required to protect the entire population. This dose range study aimed to identify priming antigen and adjuvant doses resulting in optimal levels of antibody-mediated protection after primary and one-year booster immunizations. METHODS This randomised trial enrolled 410 healthy adult (18-60 years… (More)
DOI: 10.1016/j.vaccine.2012.03.017


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics